IN2012DN00908A - - Google Patents

Info

Publication number
IN2012DN00908A
IN2012DN00908A IN908DEN2012A IN2012DN00908A IN 2012DN00908 A IN2012DN00908 A IN 2012DN00908A IN 908DEN2012 A IN908DEN2012 A IN 908DEN2012A IN 2012DN00908 A IN2012DN00908 A IN 2012DN00908A
Authority
IN
India
Prior art keywords
polypeptides
factor
modified factor
methods
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Brooks Alan
Patel Chandra
Jiang Xiaoqiao
Gritzan Uwe
Apeler Heiner
Wangjun
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of IN2012DN00908A publication Critical patent/IN2012DN00908A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN908DEN2012 2009-07-31 2010-08-02 IN2012DN00908A (US07119074-20061010-C00048.png)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN00908A true IN2012DN00908A (US07119074-20061010-C00048.png) 2015-04-03

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
IN908DEN2012 IN2012DN00908A (US07119074-20061010-C00048.png) 2009-07-31 2010-08-02

Country Status (21)

Country Link
US (1) US20120164130A1 (US07119074-20061010-C00048.png)
EP (1) EP2461821A4 (US07119074-20061010-C00048.png)
JP (1) JP2013500726A (US07119074-20061010-C00048.png)
KR (1) KR20120060209A (US07119074-20061010-C00048.png)
CN (1) CN102573890A (US07119074-20061010-C00048.png)
AU (1) AU2010278721A1 (US07119074-20061010-C00048.png)
BR (1) BR112012002072A2 (US07119074-20061010-C00048.png)
CA (1) CA2769258A1 (US07119074-20061010-C00048.png)
CL (1) CL2012000238A1 (US07119074-20061010-C00048.png)
CR (1) CR20120052A (US07119074-20061010-C00048.png)
CU (3) CU20120018A7 (US07119074-20061010-C00048.png)
DO (1) DOP2012000030A (US07119074-20061010-C00048.png)
EA (1) EA201290069A1 (US07119074-20061010-C00048.png)
EC (1) ECSP12011637A (US07119074-20061010-C00048.png)
GT (1) GT201200023A (US07119074-20061010-C00048.png)
IN (1) IN2012DN00908A (US07119074-20061010-C00048.png)
MX (1) MX2012001346A (US07119074-20061010-C00048.png)
PE (1) PE20121643A1 (US07119074-20061010-C00048.png)
SG (1) SG178119A1 (US07119074-20061010-C00048.png)
WO (1) WO2011014890A1 (US07119074-20061010-C00048.png)
ZA (1) ZA201200716B (US07119074-20061010-C00048.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105838699A (zh) 2006-12-15 2016-08-10 巴克斯艾尔塔公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
EP3252157A1 (en) 2008-09-15 2017-12-06 Paolo Simioni Factor ix polypeptide mutant, its uses and a method for its production
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN102573920B (zh) 2009-07-27 2015-01-14 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
ES2856055T3 (es) 2009-07-27 2021-09-27 Baxalta GmbH Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre
US8637640B2 (en) 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8945897B2 (en) 2010-07-26 2015-02-03 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
KR102269494B1 (ko) * 2010-07-30 2021-06-25 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
ES2656613T3 (es) * 2011-12-19 2018-02-27 Dilafor Ab Glicosaminoglicanos no anticoagulantes que comprenden unidades de repetición de disacáridos y su uso médico
ES2744903T3 (es) * 2012-11-20 2020-02-26 Univ North Carolina Chapel Hill Métodos y composiciones para proteínas del factor IX modificadas
JP6423852B2 (ja) * 2013-03-13 2018-11-14 イーライ リリー アンド カンパニー 修飾されたイヌレプチンポリペプチド
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
WO2018022844A2 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1520259A (zh) * 2001-04-25 2004-08-11 ���ݴ�ѧУ��ίԱ�� 利用球状载体将第八因子/第九因子进行肝脏基因转移治疗血友病的方法
CA2549413A1 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated factor ix
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
EA201290069A1 (ru) 2012-07-30
CU20130058A7 (es) 2013-06-28
EP2461821A4 (en) 2013-07-03
US20120164130A1 (en) 2012-06-28
CA2769258A1 (en) 2011-02-03
DOP2012000030A (es) 2012-02-29
CR20120052A (es) 2012-06-04
GT201200023A (es) 2014-01-27
EP2461821A1 (en) 2012-06-13
CL2012000238A1 (es) 2012-10-05
KR20120060209A (ko) 2012-06-11
CU20120018A7 (es) 2012-06-21
CN102573890A (zh) 2012-07-11
PE20121643A1 (es) 2012-11-25
AU2010278721A1 (en) 2012-02-16
ZA201200716B (en) 2013-07-31
MX2012001346A (es) 2012-02-17
WO2011014890A1 (en) 2011-02-03
ECSP12011637A (es) 2012-02-29
JP2013500726A (ja) 2013-01-10
CU20130057A7 (es) 2013-06-28
BR112012002072A2 (pt) 2016-11-08
SG178119A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
IN2012DN00908A (US07119074-20061010-C00048.png)
MX2011007930A (es) Conjugados de insulina cristalina.
MY192475A (en) Modified factor ix polypeptides and uses thereof
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
MX356282B (es) Composiciones y metodos que comprenden variantes de proteasa.
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
GEP20146056B (en) Acylated glucagon analogues
MX355543B (es) Macrociclos peptidomiméticos.
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
IN2012DN03883A (US07119074-20061010-C00048.png)
IN2012DN02177A (US07119074-20061010-C00048.png)
MX2012007438A (es) Analogo peptidico de oxintomodulina.
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2019003619A (es) Formulaciones de bromocriptina.
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
MX2010010457A (es) Vectores recombinantes de rinovirus.
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
PH12014501200A1 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
MX2011008179A (es) Peptidos para vacuna.
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma